Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29283321 | 0.97 | TSHR (0.36) | TSHRALDH1A1TP53HCAR2 | |
| SCHEMBL9114520 | 0.87 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL9114517 | 0.84 | ALDH1A1 (0.31) | TSHRALDH1A1 | |
| SCHEMBL3422574 | 0.78 | TSHR (0.38) | TSHRALDH1A1TP53HCAR2CYP2D6 | |
| SCHEMBL31229139 | 0.74 | TSHR (0.35) | TSHRALDH1A1TP53HCAR2 | |
| SCHEMBL31331224 | 0.74 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL29283320 | 0.74 | TSHR (0.31) | TSHR | |
| SCHEMBL28995292 | 0.74 | TSHR (0.35) | TSHRALDH1A1 | |
| SCHEMBL27472912 | 0.74 | CYP2D6 (0.33) | TSHRCYP2D6CYP2C19HIF1A | |
| SCHEMBL7263307 | 0.72 | TSHR (0.33) | TSHRALDH1A1TP53HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | claimed |
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2433941-A1 | Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | Bristol-Myers Squibb Company (US) | 2012-03-28 | — | — | EP | disclosed |
| US-7968555-B2 | Intermediates in the preparation of entecavir via carbon-silicon oxidation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100286089-A1 | Process for the Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-11 | — | — | US | disclosed |
| US-7786300-B2 | Process for preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7550619-B2 | Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090143578-A1 | Process for Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-7541460-B2 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-3-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1751158-A4 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | BRISTOL MYERS SQUIBB CO (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7511139-B2 | Photodesilylation, oxidation, deportection, reaction with triisopropyl orthoformate in presence of acid catalyst, further reacting acetic anhydride and acetic acid, hydrolysis with HCl to form entecavir; aniviral agent; hepatitis b | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1751158-A1 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | Brystol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | disclosed |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | PENDRI YADAGIRI R | 2006-05-18 | — | — | US | disclosed |
| US-7034152-B2 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005118585-A1 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272932-A1 | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-08 | — | — | US | disclosed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | disclosed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143578-A1 | Process for Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | SAMHD1, TYMP, SORD | TSHR 4708/4885ALDH1A1 1827/4885TP53 2120/4885 |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TSHR 4276/4885ALDH1A1 1031/4885TP53 4350/4885 |
| US-20100286089-A1 | Process for the Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | SAMHD1, TYMP, SEPTIN9 | TSHR 4709/4885ALDH1A1 1852/4885TP53 1959/4885 |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TSHR 4332/4885ALDH1A1 976/4885TP53 4066/4885 |
| US-20050272932-A1 | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | SAMHD1, TYMP, SEPTIN9 | TSHR 4709/4885ALDH1A1 1852/4885TP53 1959/4885 |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TSHR 4332/4885ALDH1A1 976/4885TP53 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.